Background:
Several therapeutic possibilities have been explored against Severe Acute Respiratory Syndrome-2
(SARS-CoV-2), such as convalescent plasma (CP), intravenous immunoglobulin (IVIG) and monoclonal antibodies. Compounds such as hydroxychloroquine have also been found to have fatal drawbacks. Repurposing of existing antiviral drugs
can be an effective strategy, which could fasten up the process of drug discovery.
Objective:
The present study is designed to predict the computational efficacy of pre-existing antiviral drugs as inhibitors for
the Nsp10-Nsp16 complex protein of SARS-CoV-2.
Method:
Twenty-six known antiviral drugs along with their similar structures based on Tanimoto similarity were screened
towards Nsp10-Nsp16 complex’s active site.
Result:
Our study reports competitive binding of 1-[3-[2-(2-Ethoxyphenoxy) ethylamino]-2-hydroxypropyl] -9H-carbazol-4-
ol against AdoMet binding site in Nsp10-Nsp16 complex. Formation of the stable ligand-receptor complex with 1-[3-[2-(2-
Ethoxyphenoxy) ethylamino]-2-hydroxypropyl] -9H-carbazol-4-ol could functionally inhibit the Nsp10-Nsp16 complex,
thereby making the SARS-CoV-2 vulnerable to host immuno-surveillance mechanisms.
Conclusion:
We conclude that these computational hits can display positive results in in-vitro trials against SARS-CoV-2.
Mutations in the AMPA receptor complex protein FRRS1L cause an inherited Huntington-like chorea-dementia syndrome
